Literature DB >> 2434608

Epitope mapping of the major Epstein-Barr virus outer envelope glycoprotein gp350/220.

L F Qualtiere, J F Decoteau, M Hassan Nasr-el-Din.   

Abstract

To understand the complete immunochemical structure of the Epstein-Barr virus (EBV) major membrane glycoprotein gp350/220, monoclonal antibodies (MAbs) reacting with this important viral antigen were isolated. Through competitive inhibition binding studies, it was determined that a group of 18 IgG MAbs recognized seven distinct epitopes on the gp350/220 molecule. Eight of these MAbs fell into a single epitope group with four of those MAbs, as well as a single MAb from another epitope group, being capable of neutralizing EBV strain B95-8 transformation of umbilical cord lymphocytes.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2434608     DOI： 10.1099/0022-1317-68-2-535

Source DB:  PubMed          Journal:  J Gen Virol        ISSN： 0022-1317            Impact factor:   3.891


  10 in total

1.  Mapping of B-cell epitopes on the polypeptide chain of the Epstein-Barr virus major envelope glycoprotein and candidate vaccine molecule gp340.

Authors:  R J Pither; C X Zhang; C Shiels; J Tarlton; S Finerty; A J Morgan
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

Review 2.  Control of viral disease: the development of Epstein-Barr virus vaccines.

Authors:  A J Morgan
Journal:  Springer Semin Immunopathol       Date:  1991

3.  Epstein-Barr virus BHRF1 micro- and stable RNAs during latency III and after induction of replication.

Authors:  Li Xing; Elliott Kieff
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

4.  Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity.

Authors:  M Khyatti; P C Patel; I Stefanescu; J Menezes
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

5.  Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes.

Authors:  J Tanner; Y Whang; J Sample; A Sears; E Kieff
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

6.  Identification of two T-cell epitopes on the candidate Epstein-Barr virus vaccine glycoprotein gp340 recognized by CD4+ T-cell clones.

Authors:  L E Wallace; J Wright; D O Ulaeto; A J Morgan; A B Rickinson
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

7.  Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule.

Authors:  Jerome E Tanner; Mathieu Coinçon; Valérie Leblond; Jing Hu; Janey M Fang; Jurgen Sygusch; Caroline Alfieri
Journal:  J Virol       Date:  2015-02-18       Impact factor: 5.103

8.  Epstein-Barr virus neutralizing and early antigen antibodies in multiple sclerosis.

Authors:  J W Lindsey; L M Hatfield; T Vu
Journal:  Eur J Neurol       Date:  2010-10       Impact factor: 6.089

9.  Construction and Characterization of a Humanized Anti-Epstein-Barr Virus gp350 Antibody with Neutralizing Activity in Cell Culture.

Authors:  Jerome E Tanner; Jing Hu; Caroline Alfieri
Journal:  Cancers (Basel)       Date:  2018-04-09       Impact factor: 6.639

10.  A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.

Authors:  Xiao Zhang; Bingchun Zhao; Mingmei Ding; Shuo Song; Yinfeng Kang; Yang Yu; Miao Xu; Tong Xiang; Ling Gao; Qisheng Feng; Qinjian Zhao; Mu-Sheng Zeng; Claude Krummenacher; Yi-Xin Zeng
Journal:  Theranostics       Date:  2020-04-27       Impact factor: 11.556
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.